Results from a new clinical trial indicate that inhaling a mixture of 25 percent nitrous oxide and oxygen can provide long-lasting relief to those who have found other antidepressants ineffective.
Ketamine can provide rapid antidepressant relief in as little as two hours that can be sustained for days to weeks.
The survey also found that 75 percent of respondents now support cannabis legalization for all purposes, with just 5 percent opposed to both recreational and medical legalization.
The use of MDMA-assisted therapy for post-traumatic stress disorder (PTSD) has now proven itself in its first phase 3 clinical trial.
This comes after the FDA also recently allowed institutes to conduct clinical trials on MDMA and its therapeutic potential in treating PTSD.
Crucially, the scientists say, the benefits of the drug came without the cost of hallucinations, a side effect which may aggravate stress.
Analytical Cannabis' sister publication, Technology Networks, explores the benefits of psychedelic-assisted therapy.
A new technology developed by researchers at the University of California Davis promises to fast-track the development of compounds that could exploit psychedelics’ therapeutic action without hallucinogenic side effects.
A new trial has directly compared the antidepressant effects of psilocybin with a more classical antidepressant, and found that the two are matched in their mood-altering potential.